SCHEMBL20609230

SCHEMBL20609230

COc1cc(/C=N/N(C)c2nc(-c3ccccc3)cc(-c3ccccc3)n2)ccc1O

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 9/20 0.77
▸ MEN1 O00255 8/20 0.77
▸ KMT2A Q03164 8/20 0.77
▸ LMNA P02545 5/20 0.77
▸ MAPT P10636 13/20 0.67
▸ SMN1; SMN2 Q16637 4/20 0.67
▸ RAB9A P51151 4/20 0.67
▸ NPC1 O15118 2/20 0.67
▸ NFKB1 P19838 1/20 0.67
▸ NFKB2 Q00653 1/20 0.67
▸ RELA Q04206 1/20 0.67
▸ PAX8 Q06710 1/20 0.58
▸ USP2 O75604 1/20 0.52
▸ ALDH1A1 P00352 7/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ KDM4E B2RXH2 6/20 0.48
▸ HPGD P15428 2/20 0.48
▸ SHBG P04278 1/20 0.47
▸ ALOX12 P18054 2/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20609231 1.00 GAA (0.77) GAAMEN1KMT2ALMNAMAPT
SCHEMBL19736309 1.00 GAA (0.77) GAAMEN1KMT2ALMNAMAPT
SCHEMBL822594 0.94 GAA (0.68) GAAMEN1KMT2ALMNAMAPT
SCHEMBL19736515 0.91 MEN1 (0.77) GAAMEN1KMT2ALMNAMAPT
SCHEMBL20609226 0.91 MEN1 (0.77) GAAMEN1KMT2ALMNAMAPT
SCHEMBL20609224 0.91 MEN1 (0.77) GAAMEN1KMT2ALMNAMAPT
SCHEMBL20609182 0.88 KMT2A (0.65) GAAMEN1KMT2ALMNAMAPT
SCHEMBL20609180 0.88 KMT2A (0.65) GAAMEN1KMT2ALMNAMAPT
SCHEMBL19736573 0.88 KMT2A (0.65) GAAMEN1KMT2ALMNAMAPT
SCHEMBL24784904 0.87 MEN1 (1.00) GAAMEN1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3472133-B1 PERK INHIBITORS AND USES THEREOF IN TREATING DISEASES ASSOCIATED WITH AGGREGATION-PRONE PROTEINS UNIV RAMOT (IL) 2023-10-11 — — EP disclosed
US-20200331865-A1 PERK INHIBITORS AND USES THEREOF IN TREATING DISEASES ASSOCIATED WITH AGGREGATION-PRONE PROTEINS RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2020-10-22 — — US disclosed
US-10723706-B2 Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2020-07-28 — — US disclosed
US-20190010130-A1 PERK INHIBITORS AND USES THEREOF IN TREATING DISEASES ASSOCIATED WITH AGGREGATION-PRONE PROTEINS RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2019-01-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190010130-A1 PERK INHIBITORS AND USES THEREOF IN TREATING DISEASES ASSOCIATED WITH AGGREGATION-PRONE PROTEINS XBP1, HSPA5, HSPA4 GAA 863/4885MEN1 4546/4885KMT2A 4012/4885
US-20200331865-A1 PERK INHIBITORS AND USES THEREOF IN TREATING DISEASES ASSOCIATED WITH AGGREGATION-PRONE PROTEINS XBP1, HSPA5, HSPA4 GAA 863/4885MEN1 4546/4885KMT2A 4012/4885
US-10723706-B2 Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins XBP1, HSPA5, HSPA4 GAA 863/4885MEN1 4546/4885KMT2A 4012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback